GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Voyageur Pharmaceuticals Ltd (TSXV:VM) » Definitions » Capex-to-Revenue

Voyageur Pharmaceuticals (TSXV:VM) Capex-to-Revenue : 0.00 (As of Aug. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Voyageur Pharmaceuticals Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Voyageur Pharmaceuticals's Capital Expenditure for the three months ended in Aug. 2024 was C$0.00 Mil. Its Revenue for the three months ended in Aug. 2024 was C$0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Voyageur Pharmaceuticals Capex-to-Revenue Historical Data

The historical data trend for Voyageur Pharmaceuticals's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyageur Pharmaceuticals Capex-to-Revenue Chart

Voyageur Pharmaceuticals Annual Data
Trend Dec14 Dec15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Voyageur Pharmaceuticals Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Voyageur Pharmaceuticals's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Voyageur Pharmaceuticals's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyageur Pharmaceuticals's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Voyageur Pharmaceuticals's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Voyageur Pharmaceuticals's Capex-to-Revenue falls into.



Voyageur Pharmaceuticals Capex-to-Revenue Calculation

Voyageur Pharmaceuticals's Capex-to-Revenue for the fiscal year that ended in Nov. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

Voyageur Pharmaceuticals's Capex-to-Revenue for the quarter that ended in Aug. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Voyageur Pharmaceuticals  (TSXV:VM) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Voyageur Pharmaceuticals Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Voyageur Pharmaceuticals's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Voyageur Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4103B Center Street NW, Suite 800, Calgary, AB, CAN, T2E 2Y6
Voyageur Pharmaceuticals Ltd is engaged in acquiring, exploring and developing raw materials for pharmaceutical products.
Executives
Bradley Craig Willis Director, Senior Officer
Trent Abraham Director
Charles Littlejohn 10% Security Holder

Voyageur Pharmaceuticals Headlines

No Headlines